ARTICLE | Clinical News
MRX-4: Phase II data
November 10, 2008 8:00 AM UTC
Top-line data from a double-blind, South African Phase II trial in 105 patients with allergic rhinitis showed that MRX-4 significantly reduced a composite of 6 rhinitis symptoms (rhinorrhea, nasal itc...